The company’s pharmaceutical sales recorded a 1% rise to $12.18bn compared to $12.03bn in the prior-year quarter.
For the quarter, GAAP earnings per share (EPS) from continuing operations was $1.18, indicating a 22% decline from $1.5 in the same quarter last year.
Non-GAAP EPS was recorded at $1.62, a 10% decrease from $1.81 in the previous year’s quarter.
Merck has reported a 22% increase in worldwide sales for the full-year 2022, to $59.28bn from $48.7bn in the prior-year quarter.
Its growth was 12%, omitting Lagevrio, and 15% excluding Lagevrio, as well as the impact of foreign exchange.
In full-year 2022, sales from Keytruda were reported to be $20.9bn, a growth of 22% from 2021.
Sales from Gardasil/Gardasil 9 were $6.9bn, representing a growth of 22% from 2021.
Merck’s GAAP EPS from continuing operations was $5.71, a 17% rise from $4.86 reported last year, and non-GAAP EPS stood at $7.48, indicating a 39% growth.
Merck chairman and CEO Robert Davis said: “2022 was an exceptional year for Merck, which is a testament to the profound impact our medicines and vaccines are having on patients globally.
“I am extremely proud of what our talented and dedicated colleagues have accomplished scientifically, commercially and operationally.
“Our science-led strategy is working as we continue to build a sustainable engine that will drive innovation and generate long-term value for patients and shareholders well into the next decade.”
For the full-year 2023, the company expects worldwide sales between $57.2bn and $58.7bn.